Dr. Thomas R. Cimato, M.D. PH.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York at Buffalo School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 323
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: State University of New York at Buffalo School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MD license D0061287 -
Internal Medicine Physician
MD license D0061287
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Kaleida Health Buffalo, NY
Medical groups
- General Physician PC (501 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 323
- Services billed
- 1,174
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, regadenoson, 0.1 mg | 156 | 39 |
| Established patient office or other outpatient visit, 30-39 minutes | 146 | 99 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 125 | 122 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 96 | 48 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 88 | 83 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 62 | 23 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 52 | 52 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 51 | 51 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 49 | 49 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 39 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $83.65 in total to this clinician.
| Boston Scientific Corporation | $44.80 |
|---|---|
| Abbott Laboratories | $23.59 |
| E.r. Squibb & Sons, L.l.c. | $15.26 |
| Food and Beverage | $83.65 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $10,721 in research payments for these studies, mostly to the institutions running them.
- ALT-FLOW II 2022-06
Edwards Lifesciences Corporation - A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.